Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Centessa's Orexia Therapeutics, Schrodinger announce collaboration » 08:17
10/18/21
10/18
08:17
10/18/21
08:17
SDGR

Schrodinger

$55.37 /

+0.34 (+0.62%)

, CNTA

Centessa

$17.00 /

+0.7 (+4.29%)

Schrodinger (SDGR) and…

Schrodinger (SDGR) and Centessa Pharmaceuticals (CNTA), together with subsidiary Orexia Therapeutics, announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor, which is known to play a role in a broad spectrum of sleep disorders including narcolepsy. The collaboration provides Orexia with substantial access to Schrodinger's entire computational platform as well as Schrodinger's extensive expertise in ultra-large-scale deployment of its technology. Orexia will leverage Schrodinger's computational platform, including LiveDesign and Free Energy Perturbation, which facilitates high-performance calculations for drug discovery to enable accurate prediction of potency at the target of interest. The collaboration will be enabled by Orexia's structural biology capabilities, including the stabilized OX2R StaR protein exclusively licensed from Sosei Heptares, and high-resolution crystal structures in agonist conformation. The collaboration represents the first time Schrodinger's technology will be applied in an orexin agonist setting at scale. "While prevailing treatment approaches only address the symptoms associated with narcolepsy type 1, we believe orexin agonists offer a disruptive approach, with the capacity to address the underlying pathology of the disorder. Orexia's utilization of OX2R stabilized receptors provides the foundation for R&D which could significantly benefit patients with NT1. We look forward to partnering with Schrodinger to complement the discovery and development work we are conducting at Orexia," said Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa. Under the terms of the agreement, Orexia will be responsible for preclinical research activities, clinical development and commercialization of future product candidates discovered under the collaboration. Schrodinger will receive an upfront software access payment and may become eligible to receive certain preclinical, development, regulatory and commercial milestone payments, as well as low single digit royalties on global net sales.

ShowHide Related Items >><<
SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

CNTA Centessa
$17.00 /

+0.7 (+4.29%)

SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

10/13/21 Berenberg
Schrodinger initiated with a Buy at Berenberg
09/01/21
Fly Intel: Top five analyst upgrades
09/01/21 Morgan Stanley
Schrodinger upgraded to Overweight on recent selloff at Morgan Stanley
09/01/21 Morgan Stanley
Schrodinger upgraded to Overweight from Equal Weight at Morgan Stanley
CNTA Centessa
$17.00 /

+0.7 (+4.29%)

06/22/21
Fly Intel: Top five analyst initiations
06/22/21 Jefferies
Centessa initiated with a Buy at Jefferies
06/22/21 Morgan Stanley
Centessa initiated with an Overweight at Morgan Stanley
06/22/21 Goldman Sachs
Centessa initiated with a Buy at Goldman Sachs
SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

CNTA Centessa
$17.00 /

+0.7 (+4.29%)

  • 28
    May
SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

CNTA Centessa
$17.00 /

+0.7 (+4.29%)

SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

Hot Stocks
Schrodinger, Centessa announce pact to discover novel orexin receptor agonists » 08:06
10/18/21
10/18
08:06
10/18/21
08:06
SDGR

Schrodinger

$55.37 /

+0.34 (+0.62%)

, CNTA

Centessa

$17.00 /

+0.7 (+4.29%)

Schrodinger (SDGR) and…

Schrodinger (SDGR) and Centessa Pharmaceuticals (CNTA), together with subsidiary Orexia Therapeutics announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor, OX2R, which is known to play a role in a broad spectrum of sleep disorders including narcolepsy. The collaboration provides Orexia with substantial access to Schrodinger's entire computational platform as well as Schrodinger's extensive expertise in ultra-large-scale deployment of its technology. Orexia will leverage Schrodinger's computational platform, including LiveDesign and Free Energy Perturbation, FEP+, which facilitates high-performance calculations for drug discovery to enable accurate prediction of potency at the target of interest. The collaboration will be enabled by Orexia's structural biology capabilities, including the stabilized OX2R StaR protein exclusively licensed from Sosei Heptares, and high-resolution crystal structures in agonist conformation. The collaboration represents the first time Schrodinger's technology will be applied in an orexin agonist setting at scale. "While prevailing treatment approaches only address the symptoms associated with narcolepsy type 1 we believe orexin agonists offer a disruptive approach, with the capacity to address the underlying pathology of the disorder. Orexia's utilization of OX2R stabilized receptors provides the foundation for R&D which could significantly benefit patients with NT1. We look forward to partnering with Schrodinger to complement the discovery and development work we are conducting at Orexia," said Saurabh Saha, MD, PhD, Chief Executive Officer of Centessa. Under the terms of the agreement, Orexia will be responsible for preclinical research activities, clinical development and commercialization of future product candidates discovered under the collaboration. Schrodinger will receive an upfront software access payment and may become eligible to receive certain preclinical, development, regulatory and commercial milestone payments, as well as low single digit royalties on global net sales.

ShowHide Related Items >><<
SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

CNTA Centessa
$17.00 /

+0.7 (+4.29%)

SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

10/13/21 Berenberg
Schrodinger initiated with a Buy at Berenberg
09/01/21
Fly Intel: Top five analyst upgrades
09/01/21 Morgan Stanley
Schrodinger upgraded to Overweight on recent selloff at Morgan Stanley
09/01/21 Morgan Stanley
Schrodinger upgraded to Overweight from Equal Weight at Morgan Stanley
CNTA Centessa
$17.00 /

+0.7 (+4.29%)

06/22/21
Fly Intel: Top five analyst initiations
06/22/21 Jefferies
Centessa initiated with a Buy at Jefferies
06/22/21 Morgan Stanley
Centessa initiated with an Overweight at Morgan Stanley
06/22/21 Goldman Sachs
Centessa initiated with a Buy at Goldman Sachs
SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

CNTA Centessa
$17.00 /

+0.7 (+4.29%)

  • 28
    May
SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

CNTA Centessa
$17.00 /

+0.7 (+4.29%)

SDGR Schrodinger
$55.37 /

+0.34 (+0.62%)

Thursday
Recommendations
Absci coverage transferred at Cowen » 17:23
10/14/21
10/14
17:23
10/14/21
17:23
ABSI

Absci

$10.56 /

+0.16 (+1.54%)

Cowen transferred…

Cowen transferred coverage of Absci to analyst Max Masucci, who maintained a Market Perform rating on the stock.

ShowHide Related Items >><<
ABSI Absci
$10.56 /

+0.16 (+1.54%)

ABSI Absci
$10.56 /

+0.16 (+1.54%)

08/16/21 JPMorgan
Absci initiated with an Overweight at JPMorgan
08/16/21 Cowen
Cowen starts Absci at Market Perform ahead of more validating milestones
08/16/21 Stifel
Absci initiated with a Hold at Stifel
08/16/21 BofA
BofA starts Absci at Neutral with $26 price target
ABSI Absci
$10.56 /

+0.16 (+1.54%)

  • 22
    Jul
ABSI Absci
$10.56 /

+0.16 (+1.54%)

Over a week ago
Initiation
Schrodinger initiated with a Buy at Berenberg » 06:25
10/13/21
10/13
06:25
10/13/21
06:25
SDGR

Schrodinger

$51.42 /

+0.52 (+1.02%)

Berenberg analyst Gaurav…

Berenberg analyst Gaurav Goparaju initiated coverage of Schrodinger with a Buy rating and $91 price target. The company has a platform that enables more efficient drug discovery and development, Goparaju tells investors in a research note. The analyst believes Schrodinger will be a key contributor to redefining the drug discovery space.

ShowHide Related Items >><<
SDGR Schrodinger
$51.42 /

+0.52 (+1.02%)

SDGR Schrodinger
$51.42 /

+0.52 (+1.02%)

09/01/21
Fly Intel: Top five analyst upgrades
09/01/21 Morgan Stanley
Schrodinger upgraded to Overweight on recent selloff at Morgan Stanley
09/01/21 Morgan Stanley
Schrodinger upgraded to Overweight from Equal Weight at Morgan Stanley
06/11/21 BMO Capital
Schrodinger coverage transferred at BMO Capital
SDGR Schrodinger
$51.42 /

+0.52 (+1.02%)

SDGR Schrodinger
$51.42 /

+0.52 (+1.02%)

SDGR Schrodinger
$51.42 /

+0.52 (+1.02%)

Hot Stocks
Certara appoints Patrick Smith as president, integrated drug development » 08:20
10/12/21
10/12
08:20
10/12/21
08:20
CERT

Certara

$33.52 /

-0.19 (-0.56%)

Certara announced the…

Certara announced the appointment of Patrick Smith, Pharm.D. as president of Integrated Drug Development, reporting to CEO William Feehery. Smith will lead the Company's global drug development services team, which creates value for clients across the entire drug development life cycle using biosimulation and quantitative approaches. Smith succeeds Craig Rayner, Pharm.D., who has served as president of IDD since 2019 and will be appointed to the role of Certara distinguished scientist, leading key strategic client engagements and scientific innovation. Smith was most recently senior vice president of IDD strategy and innovation at Certara, where he developed the commercial team from the ground up and launched new solutions to meet customer needs.

ShowHide Related Items >><<
CERT Certara
$33.52 /

-0.19 (-0.56%)

CERT Certara
$33.52 /

-0.19 (-0.56%)

09/17/21 Baird
Certara price target raised to $41 from $32 at Baird
08/04/21 Credit Suisse
Certara assumed with a Neutral at Credit Suisse
07/23/21 Baird
Certara initiated with an Outperform at Baird
05/07/21 Barclays
Certara price target lowered to $35 from $40 at Barclays
CERT Certara
$33.52 /

-0.19 (-0.56%)

  • 09
    Sep
  • 25
    Mar
  • 11
    Dec
CERT Certara
$33.52 /

-0.19 (-0.56%)

Hot Stocks
MD Anderson and Schrodinger in strategic research pact on WEE1 program » 08:06
10/07/21
10/07
08:06
10/07/21
08:06
SDGR

Schrodinger

$51.10 /

-1.2 (-2.29%)

The University of Texas…

The University of Texas MD Anderson Cancer Center and Schrodinger, announced a two-year strategic research collaboration focused on accelerating and optimizing the development of Schrodinger's WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase. Under the preclinical collaboration agreement, Schrodinger will join forces with researchers in MD Anderson's Translational Research to AdvanCe Therapeutics and Innovation in ONcology TRACTION platform, which leads cutting-edge translational biology research to rapidly position new therapies for clinical trials. TRACTION is a core component of MD Anderson's Therapeutics Discovery division, an integrated team of clinicians, researchers and drug development experts working to advance impactful therapies that address patient needs. MD Anderson and Schrodinger will jointly pursue translational studies, and Schrodinger will provide research support funding. As part of the agreement, MD Anderson is eligible to receive certain payments based on the future development and commercialization of Schrodinger's WEE1 inhibitor compounds. Schrodinger will have sole responsibility for the development, manufacture and commercialization of all compounds and products, and sole rights to all novel intellectual property that arises from this collaboration.

ShowHide Related Items >><<
SDGR Schrodinger
$51.10 /

-1.2 (-2.29%)

SDGR Schrodinger
$51.10 /

-1.2 (-2.29%)

09/01/21
Fly Intel: Top five analyst upgrades
09/01/21 Morgan Stanley
Schrodinger upgraded to Overweight on recent selloff at Morgan Stanley
09/01/21 Morgan Stanley
Schrodinger upgraded to Overweight from Equal Weight at Morgan Stanley
06/11/21 BMO Capital
Schrodinger coverage transferred at BMO Capital
SDGR Schrodinger
$51.10 /

-1.2 (-2.29%)

SDGR Schrodinger
$51.10 /

-1.2 (-2.29%)

SDGR Schrodinger
$51.10 /

-1.2 (-2.29%)

Hot Stocks
Absci and EQRx partner to develop protein-based drugs » 06:06
10/06/21
10/06
06:06
10/06/21
06:06
ABSI

Absci

$11.06 /

+0.16 (+1.47%)

Absci and EQRx, a…

Absci and EQRx, a pharmaceutical company launched in January 2020, announced a discovery collaboration. The partnership will leverage Absci's Drug Creation technology for discovery and development activities, along with EQRx's clinical development expertise and commercial capabilities, to advance protein-based therapeutics. EQRx and Absci will collaborate to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology. At Absci's option, it may make additional investments at progressive stages of development in exchange for an increased share of product sales. In August 2021, EQRx announced a proposed combination with CM Life Sciences III to accelerate its growth. The combination is expected to be completed in Q4.

ShowHide Related Items >><<
ABSI Absci
$11.06 /

+0.16 (+1.47%)

08/16/21 JPMorgan
Absci initiated with an Overweight at JPMorgan
08/16/21 Cowen
Cowen starts Absci at Market Perform ahead of more validating milestones
08/16/21 Stifel
Absci initiated with a Hold at Stifel
08/16/21 BofA
BofA starts Absci at Neutral with $26 price target
ABSI Absci
$11.06 /

+0.16 (+1.47%)

  • 22
    Jul
ABSI Absci
$11.06 /

+0.16 (+1.47%)

Hot Stocks
Certara appoints Drayton Virkler as Chief Commercial Officer » 08:10
10/05/21
10/05
08:10
10/05/21
08:10
CERT

Certara

$32.04 /

-2.85 (-8.17%)

, IQV

Iqvia

$238.56 /

-2.82 (-1.17%)

Certara (CERT) announced…

Certara (CERT) announced the appointment of Drayton Virkler to the newly created position of Chief Commercial Officer. In this role, Virkler will drive the Company's global commercial strategy and execution and expand the business development team. Virkler was most recently at IQVIA (IQV) for a decade, where he served as Vice President and Global Head of Sales for the Real World Solutions Global Business Unit.

ShowHide Related Items >><<
IQV Iqvia
$238.56 /

-2.82 (-1.17%)

CERT Certara
$32.04 /

-2.85 (-8.17%)

CERT Certara
$32.04 /

-2.85 (-8.17%)

09/17/21 Baird
Certara price target raised to $41 from $32 at Baird
08/04/21 Credit Suisse
Certara assumed with a Neutral at Credit Suisse
07/23/21 Baird
Certara initiated with an Outperform at Baird
05/07/21 Barclays
Certara price target lowered to $35 from $40 at Barclays
IQV Iqvia
$238.56 /

-2.82 (-1.17%)

09/10/21 Argus
Iqvia price target raised to $290 from $260 at Argus
08/04/21 Credit Suisse
Iqvia assumed with an Outperform at Credit Suisse
07/28/21 Piper Sandler
Iqvia price target raised to $235 from $204 at Piper Sandler
07/28/21 Deutsche Bank
Iqvia price target raised to $250 from $244 at Deutsche Bank
IQV Iqvia
$238.56 /

-2.82 (-1.17%)

CERT Certara
$32.04 /

-2.85 (-8.17%)

  • 09
    Sep
  • 25
    Mar
  • 11
    Dec
CERT Certara
$32.04 /

-2.85 (-8.17%)

Hot Stocks
Certara completes acquisition of Pinnacle 21 » 08:26
10/04/21
10/04
08:26
10/04/21
08:26
CERT

Certara

$34.89 /

+1.8 (+5.44%)

Certara announced the…

Certara announced the completion of the previously announced transaction to acquire Pinnacle 21, a provider of SaaS solutions for clinical data fitness, regulatory compliance and submission readiness. At closing, equity holders of Pinnacle 21 received approximately $250 million in cash consideration and 2,239,717 shares of Certara restricted common stock, subject to certain customary closing adjustments. The transaction is expected to be accretive to Certara's revenue, revenue growth, and adjusted EBITDA. Certara will update financial guidance when the Company releases third quarter 2021 earnings in November.

ShowHide Related Items >><<
CERT Certara
$34.89 /

+1.8 (+5.44%)

CERT Certara
$34.89 /

+1.8 (+5.44%)

09/17/21 Baird
Certara price target raised to $41 from $32 at Baird
08/04/21 Credit Suisse
Certara assumed with a Neutral at Credit Suisse
07/23/21 Baird
Certara initiated with an Outperform at Baird
05/07/21 Barclays
Certara price target lowered to $35 from $40 at Barclays
CERT Certara
$34.89 /

+1.8 (+5.44%)

  • 09
    Sep
  • 25
    Mar
  • 11
    Dec
CERT Certara
$34.89 /

+1.8 (+5.44%)

On The Fly
Wall Street in Fives - Must Read Lists for Friday » 16:23
10/01/21
10/01
16:23
10/01/21
16:23
MRK

Merck

$81.39 /

+6.27 (+8.35%)

, FIVN

Five9

$167.23 /

+7.4 (+4.63%)

, ZM

Zoom Video

$267.57 /

+5.71 (+2.18%)

, GM

General Motors

$53.14 /

+0.44 (+0.83%)

, EA

Electronic Arts

$143.51 /

+1.13 (+0.79%)

, GH

Guardant Health

$107.57 /

-17.53 (-14.01%)

, NEO

NeoGenomics

$48.50 /

+0.21 (+0.43%)

, GOOGL

Alphabet Class A

$2,728.65 /

+55.74 (+2.09%)

, GOOG

Alphabet

$2,725.73 /

+62.66 (+2.35%)

, DIS

Disney

$176.11 /

+6.96 (+4.11%)

, COIN

Coinbase

$231.15 /

+3.69 (+1.62%)

, IBM

IBM

$143.33 /

+4.4 (+3.17%)

, BABA

Alibaba

$144.20 /

-3.84 (-2.59%)

, MGM

MGM Resorts

$44.86 /

+1.72 (+3.99%)

, DKNG

DraftKings

$50.53 /

+2.36 (+4.90%)

, GMVHF

Entain

$29.59 /

-0.212 (-0.71%)

, NFLX

Netflix

$612.88 /

+2.41 (+0.39%)

, DLTR

Dollar Tree

$97.92 /

+2.25 (+2.35%)

, TMC

The Metals Company

$5.17 /

+0.59 (+12.88%)

, VLTA

Volta

$9.39 /

+0.76 (+8.81%)

, OMER

Omeros

$8.54 /

-5.285 (-38.24%)

, CGC

Canopy Growth

$13.41 /

-0.44 (-3.18%)

, QUIK

QuickLogic

$5.80 /

+0.48 (+9.02%)

, GWRE

Guidewire

$118.54 /

-0.61 (-0.51%)

, ALLE

Allegion

$132.42 /

+0.23 (+0.17%)

, COTY

Coty

$8.18 /

+0.325 (+4.14%)

, KKR

KKR

$61.67 /

+0.76 (+1.25%)

, MRNA

Moderna

$340.38 /

-44.76 (-11.62%)

, PFE

Pfizer

$42.93 /

-0.07 (-0.16%)

, ABCL

AbCellera

$17.20 /

-2.87 (-14.30%)

, ADGI

Adagio Therapeutics

$28.03 /

-13.98 (-33.28%)

, AAL

American Airlines

$21.64 /

+1.13 (+5.51%)

, UAL

United Airlines

$51.33 /

+3.72 (+7.81%)

, DAL

Delta Air Lines

$45.38 /

+2.77 (+6.50%)

, LUV

Southwest

$54.37 /

+2.94 (+5.72%)

, JBLU

JetBlue

$16.30 /

+1.02 (+6.68%)

Get caught up quickly on…

ShowHide Related Items >><<
ZM Zoom Video
$267.57 /

+5.71 (+2.18%)

VLTA Volta
$9.39 /

+0.76 (+8.81%)

UAL United Airlines
$51.33 /

+3.72 (+7.81%)

TMC The Metals Company
$5.17 /

+0.59 (+12.88%)

QUIK QuickLogic
$5.80 /

+0.48 (+9.02%)

PFE Pfizer
$42.93 /

-0.07 (-0.16%)

OMER Omeros
$8.54 /

-5.285 (-38.24%)

NFLX Netflix
$612.88 /

+2.41 (+0.39%)

NEO NeoGenomics
$48.50 /

+0.21 (+0.43%)

MRNA Moderna
$340.38 /

-44.76 (-11.62%)

MRK Merck
$81.39 /

+6.27 (+8.35%)

MGM MGM Resorts
$44.86 /

+1.72 (+3.99%)

LUV Southwest
$54.37 /

+2.94 (+5.72%)

KKR KKR
$61.67 /

+0.76 (+1.25%)

JBLU JetBlue
$16.30 /

+1.02 (+6.68%)

IBM IBM
$143.33 /

+4.4 (+3.17%)

GWRE Guidewire
$118.54 /

-0.61 (-0.51%)

GOOGL Alphabet Class A
$2,728.65 /

+55.74 (+2.09%)

GOOG Alphabet
$2,725.73 /

+62.66 (+2.35%)

GMVHF Entain
$29.59 /

-0.212 (-0.71%)

GM General Motors
$53.14 /

+0.44 (+0.83%)

GH Guardant Health
$107.57 /

-17.53 (-14.01%)

FIVN Five9
$167.23 /

+7.4 (+4.63%)

EA Electronic Arts
$143.51 /

+1.13 (+0.79%)

DLTR Dollar Tree
$97.92 /

+2.25 (+2.35%)

DKNG DraftKings
$50.53 /

+2.36 (+4.90%)

DIS Disney
$176.11 /

+6.96 (+4.11%)

DAL Delta Air Lines
$45.38 /

+2.77 (+6.50%)

COTY Coty
$8.18 /

+0.325 (+4.14%)

COIN Coinbase
$231.15 /

+3.69 (+1.62%)

CGC Canopy Growth
$13.41 /

-0.44 (-3.18%)

BABA Alibaba
$144.20 /

-3.84 (-2.59%)

ALLE Allegion
$132.42 /

+0.23 (+0.17%)

ADGI Adagio Therapeutics
$28.03 /

-13.98 (-33.28%)

ABCL AbCellera
$17.20 /

-2.87 (-14.30%)

AAL American Airlines
$21.64 /

+1.13 (+5.51%)

MRK Merck
$81.39 /

+6.27 (+8.35%)

10/01/21 Morgan Stanley
Maravai selloff on Merck's molnupiravir data overdone, says Morgan Stanley
10/01/21 Piper Sandler
Piper says view on Regeneron antibody 'less certain' after Merck 'game changer'
10/01/21 Craig-Hallum
Craig-Hallum keeps Buy rating on Codexis, thinks involved on Merck COVID pill
10/01/21 Benchmark
Codexis spike due to speculation related to Merck COVID pill, says Benchmark
FIVN Five9
$167.23 /

+7.4 (+4.63%)

10/01/21 Northland
Five9 upgraded to Outperform from Market Perform at Northland
10/01/21 Colliers
Five9 upgraded to Buy from Neutral at Colliers
10/01/21 Canaccord
Canaccord upgrades Five9 to Buy, sees opportunity in deal termination
10/01/21 Evercore ISI
Evercore ISI upgrades Five9 to Outperform after Zoom deal break
ZM Zoom Video
$267.57 /

+5.71 (+2.18%)

GM General Motors
$53.14 /

+0.44 (+0.83%)

10/01/21 Credit Suisse
GM investor day to highlight growth opportunities, says Credit Suisse
09/26/21 Goldman Sachs
General Motors price target lowered to $59 from $62 at Goldman Sachs
09/24/21 Citi
GM investor day could be 'significant positive catalyst,' says Citi
09/13/21 Barclays
General Motors price target lowered to $68 from $71 at Barclays
EA Electronic Arts
$143.51 /

+1.13 (+0.79%)

09/15/21 KeyBanc
EA's delay of Battlefield 2042 slight positive for Activision, says KeyBanc
09/15/21 Benchmark
EA shares reacting negatively to Battlefield 2042 delay rumors, says Benchmark
09/15/21 Raymond James
Delay of EA's Battlefield 2042 likely a 'mild negative,' says Raymond James
09/15/21 Truist
Battlefield 2042 delay would be 'modest negative' for EA, says Truist
GH Guardant Health
$107.57 /

-17.53 (-14.01%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
NEO NeoGenomics
$48.50 /

+0.21 (+0.43%)

08/26/21 Benchmark
NeoGenomics price target raised to $50 from $46 at Benchmark
06/03/21 Goldman Sachs
NeoGenomics initiated with a Buy at Goldman Sachs
05/25/21 Truist
NeoGenomics price target lowered to $54 from $65 at Truist
02/25/21 Craig-Hallum
NeoGenomics price target raised to $65 from $50 at Craig-Hallum
GOOGL Alphabet Class A
$2,728.65 /

+55.74 (+2.09%)

09/30/21 RBC Capital
Alphabet initiated with an Outperform at RBC Capital
09/27/21 BofA
Roku selloff overdone as streaming lead remains, says BofA
09/17/21 Jefferies
Alphabet price target raised to $3,325 from $3,150 at Jefferies
09/13/21
Fly Intel: Top five analyst initiations
GOOG Alphabet
$2,725.73 /

+62.66 (+2.35%)

09/13/21 Goldman Sachs
Alphabet Class A initiated with a Buy at Goldman Sachs
DIS Disney
$176.11 /

+6.96 (+4.11%)

09/28/21 Wells Fargo
Wells Fargo cuts Disney target, sees 'wood to chop' to hit sub outlook
09/22/21 BofA
Disney's Q4 Disney+ subscriber adds estimate cut to 2M from 14M at BofA
09/21/21 KeyBanc
Disney+ subscriber guidance 'a very modest incremental negative,' says KeyBanc
09/21/21 Daiwa
Disney initiated with a Buy at Daiwa
COIN Coinbase
$231.15 /

+3.69 (+1.62%)

09/28/21
Fly Intel: Top five analyst initiations
09/28/21 JMP Securities
Coinbase initiated with an Outperform at JMP Securities
09/14/21 Piper Sandler
Coinbase recent selloff overdone, says Piper Sandler
09/08/21 Cowen
SEC's Coinbase action likely a broader crackdown on crypto lending, says Cowen
IBM IBM
$143.33 /

+4.4 (+3.17%)

10/01/21
Fly Intel: Top five analyst initiations
10/01/21 Jefferies
IBM initiated with a Buy at Jefferies
07/20/21
Fly Intel: Top five analyst upgrades
07/20/21 Morgan Stanley
IBM price target raised to $164 from $152 at Morgan Stanley
BABA Alibaba
$144.20 /

-3.84 (-2.59%)

10/01/21
Fly Intel: Top five analyst downgrades
10/01/21 KeyBanc
Alibaba price target lowered to $200 from $250 at KeyBanc
10/01/21 Raymond James
Alibaba downgraded to Outperform from Strong Buy at Raymond James
10/01/21 Raymond James
Alibaba downgraded to Outperform from Strong Buy at Raymond James
MGM MGM Resorts
$44.86 /

+1.72 (+3.99%)

10/01/21 Susquehanna
Susquehanna cuts MGM to Negative on digital prospects hit from DraftKings bid
10/01/21 Susquehanna
MGM Resorts downgraded to Negative from Neutral at Susquehanna
09/24/21 Credit Suisse
As Macau locks down, Credit Suisse warns of downside risk to 2022 GGR estimates
DKNG DraftKings
$50.53 /

+2.36 (+4.90%)

09/22/21 Craig-Hallum
Craig-Hallum says DraftKings deal outcome 'unanimously negative for competitors'
09/21/21 Jefferies
Jefferies sees takeout value for Entain at least GBp 2,820 per share
GMVHF Entain
$29.59 /

-0.212 (-0.71%)

09/23/21 JPMorgan
Entain price target raised to 2,570 GBp from 2,450 GBp at JPMorgan
NFLX Netflix
$612.88 /

+2.41 (+0.39%)

10/01/21 Guggenheim
Netflix price target raised to $685 from $600 at Guggenheim
09/29/21 KeyBanc
Netflix content resonating with users, says KeyBanc
09/29/21 Benchmark
Netflix price target raised to $493 from $448 at Benchmark
09/28/21 Evercore ISI
Four of top 10 most popular Netflix shows have releases in Q4, says Evercore ISI
DLTR Dollar Tree
$97.92 /

+2.25 (+2.35%)

10/01/21 KeyBanc
Dollar Tree downgraded to Sector Weight from Overweight at KeyBanc
09/30/21 KeyBanc
Dollar Tree downgraded to Sector Weight from Overweight at KeyBanc
09/29/21 Jefferies
Added price points could have multiple benefits for Dollar Tree, says Jefferies
08/27/21 Telsey Advisory
Telsey downgrades Dollar Tree on inability to pass on higher costs
TMC The Metals Company
$5.17 /

+0.59 (+12.88%)

05/27/21 Northland
Sustainable Opportunities Acquisition initiated with an Outperform at Northland
VLTA Volta
$9.39 /

+0.76 (+8.81%)

10/01/21 Roth Capital
Volta initiated with a Buy at Roth Capital
09/22/21 Needham
Volta initiated with a Buy at Needham
09/01/21 Raymond James
Volta's adjusted EBITDA should turn positive in 2023, says Raymond James
09/01/21 Raymond James
Volta initiated with an Outperform at Raymond James
OMER Omeros
$8.54 /

-5.285 (-38.24%)

10/01/21 Wedbush
Omeros downgraded to Underperform at Wedbush after 'major setback'
10/01/21 Wedbush
Omeros downgraded to Underperform from Neutral at Wedbush
10/01/21 Maxim
Omeros downgraded to Hold from Buy at Maxim
09/27/21 JPMorgan
Omeros initiated with a Neutral at JPMorgan
CGC Canopy Growth
$13.41 /

-0.44 (-3.18%)

10/01/21 BofA
Canopy Growth downgraded to Neutral at BofA on near-term sales risk
10/01/21 BofA
Canopy Growth downgraded to Neutral from Buy at BofA
09/23/21 CIBC
Canopy Growth price target lowered to C$22 from C$27 at CIBC
QUIK QuickLogic
$5.80 /

+0.48 (+9.02%)

05/19/21 Roth Capital
QuickLogic upgraded to Buy from Neutral at Roth Capital
GWRE Guidewire
$118.54 /

-0.61 (-0.51%)

09/03/21 JPMorgan
Guidewire price target raised to $160 from $145 at JPMorgan
09/03/21 BTIG
Guidewire price target raised to $138 from $130 at BTIG
09/03/21 Citi
Guidewire price target raised to $138 from $115 at Citi
07/16/21 Stifel
Guidewire transferred with Hold rating at Stifel
ALLE Allegion
$132.42 /

+0.23 (+0.17%)

09/10/21
Fly Intel: Top five analyst upgrades
09/10/21 Goldman Sachs
Allegion upgraded to Buy from Neutral at Goldman Sachs
07/23/21 Barclays
Allegion price target raised to EUR 176 from EUR 165 at Barclays
04/06/21
Fly Intel: Top five analyst upgrades
COTY Coty
$8.18 /

+0.325 (+4.14%)

09/09/21 Deutsche Bank
Coty secondary offering sends 'negative signal,' says Deutsche Bank
08/27/21 Deutsche Bank
Coty price target raised to $10 from $9 at Deutsche Bank
08/27/21 Wells Fargo
Coty price target raised to $8 from $6 at Wells Fargo
08/18/21 Stifel
Ulta Beauty price target raised to $385 from $330 at Stifel
KKR KKR
$61.67 /

+0.76 (+1.25%)

09/13/21 Citi
Citi ups KKR target to Street-high, opens 'Positive Catalyst Watch"
09/10/21 Truist
Apple will likely appeal ruling in Epic case, says Truist
08/11/21 Deutsche Bank
KKR upgraded to Buy on durable earnings power at Deutsche Bank
08/11/21 Deutsche Bank
KKR upgraded to Buy from Hold at Deutsche Bank
MRNA Moderna
$340.38 /

-44.76 (-11.62%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
08/12/21 Wells Fargo
Wells says Moderna vaccine looks more effective than Pfizer's against Delta
08/06/21
Fly Intel: Top five analyst downgrades
PFE Pfizer
$42.93 /

-0.07 (-0.16%)

09/27/21 Barrington
Barrington says Somatrogon delay does not change Opko Health view
09/24/21 Piper Sandler
Piper confident in Opko's somatrogon approval despite BLA review delay
09/24/21 Morgan Stanley
Morgan Stanley says CDC call 'modest narrowing' of Pfizer booster recommendation
ABCL AbCellera
$17.20 /

-2.87 (-14.30%)

10/01/21 Stifel
AbCellera, Adagio reactions to Merck data look 'overdone,' says Stifel
06/11/21 BMO Capital
AbCellera coverage transferred at BMO Capital
03/30/21 SVB Leerink
AbCellera price target lowered to $45 from $52 at SVB Leerink
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
ADGI Adagio Therapeutics
$28.03 /

-13.98 (-33.28%)

08/31/21
Fly Intel: Top five analyst initiations
08/31/21 Guggenheim
Adagio Therapeutics initiated with a Buy at Guggenheim
08/31/21 Stifel
Adagio Therapeutics initiated with a Buy at Stifel
AAL American Airlines
$21.64 /

+1.13 (+5.51%)

08/11/21 Redburn
American Airlines initiated with a Buy at Redburn
07/27/21
Fly Intel: Top five analyst upgrades
07/27/21 Susquehanna
American Airlines upgraded to Neutral at Susquehanna
07/27/21 Susquehanna
American Airlines upgraded to Neutral from Negative at Susquehanna
UAL United Airlines
$51.33 /

+3.72 (+7.81%)

08/11/21 Redburn
United Airlines initiated with a Sell at Redburn
07/22/21 MKM Partners
United Airlines price target lowered to $61 from $65 at MKM Partners
07/22/21 Susquehanna
United Airlines price target lowered to $51 from $56 at Susquehanna
07/13/21
Fly Intel: Top five analyst downgrades
DAL Delta Air Lines
$45.38 /

+2.77 (+6.50%)

09/24/21 Deutsche Bank
Delta Air Lines named short-term buy idea at Deutsche Bank
09/23/21
Fly Intel: Top five analyst downgrades
09/23/21 Argus
Delta Air Lines downgraded to Hold from Buy at Argus
09/23/21 Argus
Delta Air Lines downgraded to Hold from Buy at Argus
LUV Southwest
$54.37 /

+2.94 (+5.72%)

10/01/21
Fly Intel: Top five analyst upgrades
10/01/21 JPMorgan
Southwest upgraded to Overweight with $70 target at JPMorgan
10/01/21 JPMorgan
Southwest upgraded to Overweight from Neutral at JPMorgan
JBLU JetBlue
$16.30 /

+1.02 (+6.68%)

07/28/21 Susquehanna
JetBlue price target lowered to $21 from $24 at Susquehanna
06/09/21 MKM Partners
JetBlue initiated with a Neutral at MKM Partners
06/09/21 MKM Partners
JetBlue initiated with a Neutral at MKM Partners
04/15/21 Barclays
JetBlue price target raised to $20 from $14 at Barclays
ZM Zoom Video
$267.57 /

+5.71 (+2.18%)

UAL United Airlines
$51.33 /

+3.72 (+7.81%)

QUIK QuickLogic
$5.80 /

+0.48 (+9.02%)

PFE Pfizer
$42.93 /

-0.07 (-0.16%)

OMER Omeros
$8.54 /

-5.285 (-38.24%)

NFLX Netflix
$612.88 /

+2.41 (+0.39%)

MRNA Moderna
$340.38 /

-44.76 (-11.62%)

MRK Merck
$81.39 /

+6.27 (+8.35%)

MGM MGM Resorts
$44.86 /

+1.72 (+3.99%)

LUV Southwest
$54.37 /

+2.94 (+5.72%)

KKR KKR
$61.67 /

+0.76 (+1.25%)

JBLU JetBlue
$16.30 /

+1.02 (+6.68%)

IBM IBM
$143.33 /

+4.4 (+3.17%)

GWRE Guidewire
$118.54 /

-0.61 (-0.51%)

GOOGL Alphabet Class A
$2,728.65 /

+55.74 (+2.09%)

GM General Motors
$53.14 /

+0.44 (+0.83%)

GH Guardant Health
$107.57 /

-17.53 (-14.01%)

FIVN Five9
$167.23 /

+7.4 (+4.63%)

EA Electronic Arts
$143.51 /

+1.13 (+0.79%)

DLTR Dollar Tree
$97.92 /

+2.25 (+2.35%)

DKNG DraftKings
$50.53 /

+2.36 (+4.90%)

DIS Disney
$176.11 /

+6.96 (+4.11%)

DAL Delta Air Lines
$45.38 /

+2.77 (+6.50%)

COTY Coty
$8.18 /

+0.325 (+4.14%)

COIN Coinbase
$231.15 /

+3.69 (+1.62%)

CGC Canopy Growth
$13.41 /

-0.44 (-3.18%)

BABA Alibaba
$144.20 /

-3.84 (-2.59%)

ALLE Allegion
$132.42 /

+0.23 (+0.17%)

ADGI Adagio Therapeutics
$28.03 /

-13.98 (-33.28%)

ABCL AbCellera
$17.20 /

-2.87 (-14.30%)

AAL American Airlines
$21.64 /

+1.13 (+5.51%)

  • 08
    Sep
  • 06
    Aug
  • 14
    Apr
  • 13
    Jan
  • 07
    Jan
  • 11
    Dec
  • 02
    Dec
  • 11
    Nov
  • 10
    Nov
  • 07
    Oct
  • 07
    Oct
ZM Zoom Video
$267.57 /

+5.71 (+2.18%)

UAL United Airlines
$51.33 /

+3.72 (+7.81%)

PFE Pfizer
$42.93 /

-0.07 (-0.16%)

NFLX Netflix
$612.88 /

+2.41 (+0.39%)

NEO NeoGenomics
$48.50 /

+0.21 (+0.43%)

MRNA Moderna
$340.38 /

-44.76 (-11.62%)

MRK Merck
$81.39 /

+6.27 (+8.35%)

MGM MGM Resorts
$44.86 /

+1.72 (+3.99%)

LUV Southwest
$54.37 /

+2.94 (+5.72%)

KKR KKR
$61.67 /

+0.76 (+1.25%)

IBM IBM
$143.33 /

+4.4 (+3.17%)

GOOGL Alphabet Class A
$2,728.65 /

+55.74 (+2.09%)

GM General Motors
$53.14 /

+0.44 (+0.83%)

GH Guardant Health
$107.57 /

-17.53 (-14.01%)

FIVN Five9
$167.23 /

+7.4 (+4.63%)

EA Electronic Arts
$143.51 /

+1.13 (+0.79%)

DLTR Dollar Tree
$97.92 /

+2.25 (+2.35%)

DKNG DraftKings
$50.53 /

+2.36 (+4.90%)

DIS Disney
$176.11 /

+6.96 (+4.11%)

DAL Delta Air Lines
$45.38 /

+2.77 (+6.50%)

COTY Coty
$8.18 /

+0.325 (+4.14%)

COIN Coinbase
$231.15 /

+3.69 (+1.62%)

CGC Canopy Growth
$13.41 /

-0.44 (-3.18%)

BABA Alibaba
$144.20 /

-3.84 (-2.59%)

AAL American Airlines
$21.64 /

+1.13 (+5.51%)

ZM Zoom Video
$267.57 /

+5.71 (+2.18%)

VLTA Volta
$9.39 /

+0.76 (+8.81%)

UAL United Airlines
$51.33 /

+3.72 (+7.81%)

TMC The Metals Company
$5.17 /

+0.59 (+12.88%)

PFE Pfizer
$42.93 /

-0.07 (-0.16%)

NFLX Netflix
$612.88 /

+2.41 (+0.39%)

MRNA Moderna
$340.38 /

-44.76 (-11.62%)

MRK Merck
$81.39 /

+6.27 (+8.35%)

MGM MGM Resorts
$44.86 /

+1.72 (+3.99%)

IBM IBM
$143.33 /

+4.4 (+3.17%)

GWRE Guidewire
$118.54 /

-0.61 (-0.51%)

GOOGL Alphabet Class A
$2,728.65 /

+55.74 (+2.09%)

GMVHF Entain
$29.59 /

-0.212 (-0.71%)

GM General Motors
$53.14 /

+0.44 (+0.83%)

GH Guardant Health
$107.57 /

-17.53 (-14.01%)

FIVN Five9
$167.23 /

+7.4 (+4.63%)

EA Electronic Arts
$143.51 /

+1.13 (+0.79%)

DLTR Dollar Tree
$97.92 /

+2.25 (+2.35%)

DKNG DraftKings
$50.53 /

+2.36 (+4.90%)

DIS Disney
$176.11 /

+6.96 (+4.11%)

DAL Delta Air Lines
$45.38 /

+2.77 (+6.50%)

COTY Coty
$8.18 /

+0.325 (+4.14%)

COIN Coinbase
$231.15 /

+3.69 (+1.62%)

CGC Canopy Growth
$13.41 /

-0.44 (-3.18%)

BABA Alibaba
$144.20 /

-3.84 (-2.59%)

ADGI Adagio Therapeutics
$28.03 /

-13.98 (-33.28%)

ABCL AbCellera
$17.20 /

-2.87 (-14.30%)

AAL American Airlines
$21.64 /

+1.13 (+5.51%)

ZM Zoom Video
$267.57 /

+5.71 (+2.18%)

VLTA Volta
$9.39 /

+0.76 (+8.81%)

UAL United Airlines
$51.33 /

+3.72 (+7.81%)

TMC The Metals Company
$5.17 /

+0.59 (+12.88%)

PFE Pfizer
$42.93 /

-0.07 (-0.16%)

NFLX Netflix
$612.88 /

+2.41 (+0.39%)

MRNA Moderna
$340.38 /

-44.76 (-11.62%)

MRK Merck
$81.39 /

+6.27 (+8.35%)

MGM MGM Resorts
$44.86 /

+1.72 (+3.99%)

LUV Southwest
$54.37 /

+2.94 (+5.72%)

KKR KKR
$61.67 /

+0.76 (+1.25%)

JBLU JetBlue
$16.30 /

+1.02 (+6.68%)

IBM IBM
$143.33 /

+4.4 (+3.17%)

GOOGL Alphabet Class A
$2,728.65 /

+55.74 (+2.09%)

GM General Motors
$53.14 /

+0.44 (+0.83%)

EA Electronic Arts
$143.51 /

+1.13 (+0.79%)

DLTR Dollar Tree
$97.92 /

+2.25 (+2.35%)

DKNG DraftKings
$50.53 /

+2.36 (+4.90%)

DIS Disney
$176.11 /

+6.96 (+4.11%)

DAL Delta Air Lines
$45.38 /

+2.77 (+6.50%)

COTY Coty
$8.18 /

+0.325 (+4.14%)

COIN Coinbase
$231.15 /

+3.69 (+1.62%)

CGC Canopy Growth
$13.41 /

-0.44 (-3.18%)

BABA Alibaba
$144.20 /

-3.84 (-2.59%)

ABCL AbCellera
$17.20 /

-2.87 (-14.30%)

AAL American Airlines
$21.64 /

+1.13 (+5.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.